Back to search results

Blood Markers for Early Pancreas Cancer

This observational study aims to find blood markers that can help detect pancreas cancer early, especially in people who are at higher risk. Researchers are looking for specific biomarkers like BRCA1, BRCA2, MET, and PALB2. The goal is to improve the chances of survival for people with pancreas cancer by finding it sooner. You might be able to join if you are at least 19 years old, can give written consent, and can attend study visits in Omaha, NE. The study is looking for 1250 participants and is currently unclear on its recruitment status. Success will be measured by the number of pancreas cancer cases diagnosed and the identification of predictive biomarkers over 10 years.

Study design
This is an observational study with a planned enrollment of 1250 participants. It is not specified if it is randomized or blinded.
What's involved
You would need to attend an in-person study visit in Omaha, NE twice a year to collect blood samples. This would continue for 10 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 10 years to measure the number of pancreas cancer cases and identify biomarkers.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03568630

Blood Markers of Early Pancreas Cancer

Recruiting
Not specifiedAges 19+Observational
University of Nebraska
~1,250 participants
Updated 2026-02-02 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of pancreas cancer cases diagnosed.
Measured over 10 years
+2 more outcomes measured

Conditions

Diabetes Mellitus, Type 2
PreDiabetes
Pancreas Cyst
Chronic Pancreatitis
Genetic Predisposition to Disease
Inherited Disease

Explore related trials

Chronic PancreatitisDiabetes MellitusGenetic Predisposition to DiseasePancreatic CystPrediabetes

Where it's being run

1 sites across 1 states
Nebraska1

Study leadership

  • Kelsey A Klute, MD · PRINCIPAL_INVESTIGATOR · University of Nebraska

Who to contact

Suzanne M Wessling, RN, BSN
[email protected]
402-559-1577
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥19
Able to provide written, informed consent
Able to attend an in-person study visit in Omaha, NE twice a year to collect blood samples
Must also meet criteria for one specific cohort. Participants who meet criteria for more than one cohort are eligible. (The intent being that potential participants must meet the criteria for at least one cohort, but are eligible if criteria are met for more than one cohort)

Exclusion

Personal history of pancreatic ductal adenocarcinoma (PDAC)
Currently receiving treatment for a cancer diagnosis (excluding long-term hormonal therapy)
Pre-diabetes on metformin for ≥ 3 years

What this trial measures

  • Number of pancreas cancer cases diagnosed.10 years

    Number of pancreas cancer cases diagnosed.

  • Biomarkers which may predict early pancreas cancer.10 years

    Biomarkers which may predict early pancreas cancer.

  • Result of MMTT which may indicate type 3c diabetes, which may be a risk factor for pancreas cancer.10 years

    Result of MMTT which may indicate type 3c diabetes, which may be a risk factor